	US 12,290,556 B2
	Swine influenza a virus vaccine
Mark A. Mogler, Ames, IA (US); Pravina Kitikoon, Overland Park, KS (US); Supraja Puttamreddy, Ames, IA (US); Erin Strait, Spring Hill, KS (US); Ruud Philip Antoon Maria Segers, Boxmeer (NL); and Basav Nagaraj, Wageningen (NL)
Assigned to Intervet Inc., Rahway (JE)
Appl. No. 16/954,583
Filed by Intervet Inc., Rahway, NJ (US)
PCT Filed Dec. 17, 2018, PCT No. PCT/EP2018/085198 § 371(c)(1), (2) Date Jun. 17, 2020, PCT Pub. No. WO2019/121513, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/607,101, filed on Dec. 18, 2017.
Prior Publication US 2020/0330585 A1, Oct. 22, 2020
Int. Cl. A61K 39/145 (2006.01); A61K 49/00 (2006.01); A61P 31/16 (2006.01); C12N 9/24 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/145 (2013.01) [A61K 49/00 (2013.01); A61P 31/16 (2018.01); C12N 9/2402 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/70 (2013.01)]

20 Claims

1. A vaccine for administration to a porcine comprising a first alphavirus RNA replicon particle that encodes a first swine influenza A virus (IAV-S) neuraminidase (NA) or an antigenic fragment thereof and a second alphavirus RNA replicon particle that encodes a second IAV-S NA or an antigenic fragment thereof, and a pharmaceutically acceptable carrier; with the proviso that the vaccine neither comprises an IAV-S hemagglutinin (HA) or an antigenic fragment thereof, nor a nucleotide sequence that encodes the IAV-S HA or the antigenic fragment thereof; and wherein the first NA and the second NA comprise amino acid sequences that have 98% identity or less.